

## ASX RELEASE

### Volpara Half Year Results Investor Conference Call

Wellington, NZ, 9 November 2017: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a digital health company focused on the early detection of breast cancer by improving quality of screening, is pleased to invite investors to join a conference call with CEO, Dr Ralph Highnam, CFO, Craig Hadfield and Dr Monica Saini, our Consultant Diagnostic Radiologist at 9am AEDT (11am NZDT) on Friday 10 November 2017.

To pre-register please follow this link:

<https://services.choruscall.com.au/diamondpass/volpara-254621-invite.html>

*You will receive a calendar notification with dial-in details and PIN for fast-track access to the call.*

**Conference ID: 254621**

#### Dial in numbers:

Australia Toll Free:	1 800 558 698
Alternate Australia Toll Free:	1 800 809 971
Australia Local:	02 9007 3187
New Zealand Toll Free:	0800 453 055
NZ Local (Auckland):	09 929 1687
NZ Local (Wellington):	04 974 7738
NZ Local (Christchurch):	03 974 2632
China Wide:	4001 200 659
Belgium:	0800 72 111
Canada:	1855 8811 339
France:	0800 913 848
Germany:	0800 182 7617
Hong Kong:	800 966 806
India:	0008 0010 08443
Indonesia:	001 803 019 3275
Ireland:	1800 948 625
Italy:	800 793 500
Japan:	0053 116 1281
Malaysia:	1800 816 294
Norway:	800 69 950
Philippines:	1800 1110 1462
Singapore:	800 101 2785
South Korea:	00 798 142 063 275
Sweden:	020 791 959
South Africa:	0800 999 976
Switzerland:	0800 820 030
Taiwan:	008 0112 7397
Thailand:	001800 156 206 3275
UAE:	8000 3570 2705

United Kingdom:	0800 051 8245
United States:	(855) 881 1339
US Local (New York):	(914) 202 3258
US Local (Los Angeles):	(909) 235 4020
US Local (Chicago):	(815) 373 2080

ENDS.

#### **About Volpara Health Technologies Limited (ASX: VHT)**

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

[www.volparasolutions.com](http://www.volparasolutions.com)

#### **For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
ralph.highnam@volparasolutions.com  
t: +64 21 149 0541

Kyahn Williamson  
WE Buchan  
kwilliamson@buchanwe.com.au  
t: +61 3 9866 4722